Responses
Immune cell therapies and immune cell engineering
Original research
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
